Journal of Diagnostics Concepts & Practice >
Current status and challenges of diagnosis and treatment of hyperthyroidism in China
Received date: 2024-05-08
Accepted date: 2024-08-02
Online published: 2024-08-25
In China, the clinical prevalence of hyperthyroidism is 0.78%, subclinical hyperthyroidism is 0.44%, and Graves' disease hyperthyroidism is 0.53%. Untreated hyperthyroidism and subclinical hyperthyroidism may increase the risk of atrial fibrillation, stroke, and other cardiovascular events, as well as osteoporosis and fractures. In special populations (such as pregnant women and the elderly), both the diagnosis and treatment of hyperthyroidism require special conside-rations. Although China has made some progress in the standardized diagnosis and treatment of hyperthyroidism, challenges remain. Despite established guidelines for diagnosis and differential diagnosis, clinical practice faces obstacles, notably due to limited access to thyroid radionuclide imaging and 131 iodine uptake rate in some hospitals. Additionally, the peak systolic velocity (PSV) in the thyroid obtained by thyroid ultrasound is not widely adopted. While clinical treatment methods align with international standards in China, there is a lack of specific guidelines on the initial dose and dose adjustment during the reduction period of antithyroid drugs (ATD). Currently, most clinicians follow the initial dose regimen re-commended by the guidelines established by the American Thyroid Association. Furthermore, indicators in both domestic and international guidelines for predicting adverse reactions to ATD remain unclear. During the ATD treatment of hyperthyroidism, the incidence of transient neutropenia is 1%-5%, and follow-up of baseline blood routine and liver function is ne-cessary. At present, there is a lack of monitoring frequency regulations and high-quality evidence-based medical support for above indice, and clinical practice has not yet established feasible indicators for predicting ATD adverse reactions. ATD-induced agranulocytosis is related to genetic susceptibility, age, drug type and dosage. HLA-B*27:05, HLA-B*38:02 and HLA-DRB1*08:03 on chromosome 6 in Chinese Han population may be susceptibility genes. Progress has been made in the diagnosis and treatment of thyroid associated ophthalmopathy (TAO) in China, with 36.7% of doctors adopting a multidisciplinary approach. Due to accessibility issues, less than 10% of patients receive biological agents to treat TAO, which is significantly lower than that in Western countries. Given these current status and challenges in China, further measures are necessary to improve the diagnosis and treatment of hyperthyroidism.
Key words： Hyperthyroidism; Diagnosis; Treatment
LI Jing , SHAN Zhongyan . Current status and challenges of diagnosis and treatment of hyperthyroidism in China[J]. Journal of Diagnostics Concepts & Practice, 2024 , 23(04) : 347 -353 . DOI: 10.16150/j.1671-2870.2024.04.001
| [1] | L I Y, TENG D, BA J, et al. Efficacy and safety of long-term universal salt iodization on thyroid disorders: epidemiological evidence from 31 provinces of Mainland China[J]. Thyroid, 2020, 30(4):568-579. |
| [2] | 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南——甲状腺功能亢进症[J]. 中华内科杂志, 2007, 46(10):876-882. |
| Compilation team of the "Chinese Thyroid Disease Diagnosis and Treatment Guidelines", Chinese Society of Endocrinology. Chinese guidelines for diagnosis and treatment of thyroid diseases - hyperthyroidism[J]. Chin J Int Med, 2007, 46(10):876-882. | |
| [3] | 中华医学会内分泌学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会核医学分会, 等. 中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J]. 中华内分泌代谢杂志, 2022, 38(8):700-748. |
| Chinese Society of Endocrinology, Chinese Endocrinologist Association, Chinese Society of Nuclear Medicine, et al. Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Chin J Endocrinol Metab, 2022, 38(8):700-748. | |
| [4] | 《妊娠和产后甲状腺疾病诊治指南》(第2版)编撰委员会, 中华医学会内分泌学分会, 中华医学会围产医学分会. 妊娠和产后甲状腺疾病诊治指南(第2版)[J]. 中华内分泌代谢杂志, 2019, 35(8):636-665. |
| Ad Hoc Writing Committee for Guidelines on diagnosis and management of thyroid diseases during pregnancy and postpartum, Chinese Society of Endocrinology, Chinese Medical Association, Chinese Society of Perinato-logy, Chinese Medical Association. Guideline on diagnosis and management of thyroid diseases during pregnancy and postpartum (2 nd edition)[J]. Chin J Endocrinol Metab, 2019, 35(8):636-665. | |
| [5] | 中华医学会老年医学分会老年内分泌代谢疾病学组, 中华医学会内分泌学分会甲状腺学组. 中国老年人甲状腺疾病诊疗专家共识(2021)[J]. 中华内分泌代谢杂志, 2021, 37(5):399-418. |
| Endocrine Metabolic Diseases Group of the Chinese Geriatrics Society, Thyroid Group of the Chinese Society of Endocrinology, Chinese Medical Association. Expert consensus on diagnosis and treatment for elderly with thyroid diseases in China (2021)[J]. Chin J Endocrinol Metab, 2021, 37(5):399-418. | |
| [6] | CHENG X, CHAI X, MA C, et al. Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated anti?TSHR immunoassay for Graves' di-sease: a Chinese multicenter study[J]. Endocrine, 2021, 71(1):139-148. |
| [7] | WANG X, TENG X, LI C, et al. A Chinese survey on clinical practice in hyperthyroidism management: comparison with recent studies and guidelines[J]. Endocr Connect, 2021, 10(9):1091-1100. |
| [8] | PENG X, WU S, BIE C, et al. Mean peak systolic veloci-ty of superior thyroid artery for the differential diagnosis of thyrotoxicosis: a diagnostic meta-analysis[J]. BMC Endocr Disord, 2019, 19(1):56. |
| [9] | CHUNG J, LEE Y J, CHOI Y J, et al. Clinical applications of Doppler ultrasonography for thyroid disease: consensus statement by the Korean Society of Thyroid Radio-logy[J]. Ultrasonography, 2020, 39(4):315-330. |
| [10] | 薛萌, 石秋玲, 谭坤能, 等. 彩色多普勒超声、甲状腺功能及甲状腺自身抗体检查在鉴别妊娠甲状腺功能亢进和Graves病中的价值[J]. 中华内科杂志, 2016, 55(6):470-473. |
| XUE M, SHI Q L, TAN K N, et al. The role of color doppler ultrasonography, thyroid function and auto antibody for the screening of Graves' disease in pregnancy[J]. Chin J Intern Med, 2016, 55(6):470-473. | |
| [11] | VILLAGELIN D, COOPER D S, BURCH H B. A 2023 international survey of clinical practice patterns in the management of Graves' disease: a decade of change[J/OL]. J Clin Endocrinol Metab, 2024-04-05[2024-08-02]. https://pubmed.ncbi.nlm.nih.gov/38577717/. |
| [12] | LI Y, YANG T, JU L, et al. Quality of life and decision regret in patients with late-hypothyroidism after radioiodine treatment for Graves' disease[J]. Clin Endocrinol (Oxf), 2024, 100(1):87-95. |
| [13] | ROSS D S, BURCH H B, COOPER D S, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10):1343-1421. |
| [14] | LIU X, QIANG W, LIU X, et al. A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice[J]. Eur J Endocrinol, 2015, 172(3):321-326. |
| [15] | WANG X, LI T, LI Y, et al. Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study[J]. J Transl Med, 2024, 22(1):318. |
| [16] | 崔雯锦, 赵月婷, 徐书杭, 等. 影响抗甲状腺药物治疗Graves病预后因素的研究[J]. 中华内分泌代谢杂志, 2021, 37(9):773-781. |
| CUI W J, ZHAO Y T, XV S H, et al. Study on the prognostic factors of Graves′ disease treated with antithyroid drugs[J]. Chin J Endocrinol Metab, 2021, 37(9):773-781. | |
| [17] | WU X, LIU H, ZHU X, et al. Efficacy and safety of methimazole ointment for patients with hyperthyroidism[J]. Environ Toxicol Pharmacol, 2013, 36(3):1109-1112. |
| [18] | XIANG P, ZHANG Y, QU X, et al. Xiehuo Xiaoying decoction inhibits Tfh cell expansion and promotes Tfr cell amplification to ameliorate Graves' disease[J]. J Ethnopharmacol, 2023, 301:115826. |
| [19] | 徐婷, 张豫文. 1例甲巯咪唑乳膏治疗口服不耐受的甲状腺功能亢进症病例报道[J]. 上海交通大学学报(医学版), 2024, 44(3):412-416. |
| XV T, ZHANG Y W. A case report of hyperthyroidism with intolerance of oral medication with methimazole cream[J]. J Shanghai Jiao Tong Univ (Med Sci), 2024, 44(3):412-416. | |
| [20] | CHEN W T, CHI C C. Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A syste-matic review and meta-analysis of pharmacogenomics studies[J]. Br J Clin Pharmacol, 2019, 85(9):1878-1887. |
| [21] | DAI W X, LIAN X L, LU L, et al. Effect of universal salt iodization on antithyroid drugs[J]. Chin Med J (Engl), 2006, 119(13):1108-1112. |
| [22] | HUANG H, SHI Y, LIANG B, et al. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction[J]. Clin Endocrinol (Oxf), 2018, 88(3):473-478. |
| [23] | XIE Q, ZHANG X, MA J, et al. Effect of iodine nutritional status on the recurrence of hyperthyroidism and antithyroid drug efficacy in adult patients with Graves' disea-se: a systemic review[J]. Front Endocrinol (Lausanne), 2023, 14:1234918. |
| [24] | 中华医学会眼科学分会眼整形眼眶病学组, 中华医学会内分泌学分会甲状腺学组. 中国甲状腺相关眼病诊断和治疗指南(2022年)[J]. 中华眼科杂志, 2022, 58(9):646-668. |
| Oculoplastic and Orbital Disease Group of Chinese Ophthalmological Society of Chinese Medical Association, Thyroid Group of Chinese Society of Endocrinology of Chinese Medical Association. Chinese guideline on the diagnosis and treatment of thyroid-associated ophthalmopathy (2022)[J]. Chin J Ophthalmol, 2022, 58(9):646-668. | |
| [25] | YAN C, ZHANG Z, ZHANG G, et al. An ensemble deep learning diagnostic system for determining Clinical Activi-ty Scores in thyroid-associated ophthalmopathy: integra-ting multi-view multimodal images from anterior segment slit-lamp photographs and facial images[J]. Front Endocrinol (Lausanne), 2024, 15:1365350. |
| [26] | XIA D, ZHANG H, WANG H, et al. Whole-orbit-based multiparametric assessment of disease activity of thyroid eye disease on Dixon MRI[J]. Int Ophthalmol, 2024, 44(1):213 |
| [27] | LIU D, DUAN Y, HUANG K, et al. Assessing the relationship between levator palpebrae superioris and thyroid-associated ophthalmopathy using the Dixon-T2WI sequence[J]. Front Endocrinol (Lausanne), 2024, 15:1387217. |
| [28] | SUN L, PENG R, SUN R. New Multi-Parameters Combination of Technetium-99m-Diethylene-Triamine-Pentaace-tate Orbital Single-Photon Emission Computed Tomography/Computed Tomography for the Evaluation of Graves' Orbitopathy Activity[J]. Semin Ophthalmol, 2024, 39(5):387-393. |
| [29] | MA L, WANG M, ZHANG Z, et al. Three-dimensional soft tissue reconstruction and volume measurement used for the diagnosis of dysthyroid optic neuropathy[J]. Graefes Arch Clin Exp Ophthalmol, 2024, 262(6):1919-1924. |
| [30] | CHEN J, LI C, TENG W, et al. A Chinese survey of clinical practice on the management of thyroid eye disease[J]. Eur Thyroid J, 2024, 13(3):e230269. |
| [31] | ZHANG H, HU H, WANG Y, et al. Predicting glucocorticoid effectiveness in thyroid eye disease: combined value from serological lipid metabolism and an orbital MRI parameter[J]. Eur Thyroid J, 2024, 13(1):e230109. |
| [32] | LI Z, LUO Y, HUANG Q, et al. A randomized clinical trial of intravenous methylprednisolone with 2 protocols in patients with Graves orbitopathy[J]. J Clin Endocrinol Metab, 2023, 109(1):36-45. |
| [33] | JANSEN H I, HEUVELING VAN BEEK C, BISSCHOP P H, et al. The need for the GREAT+?score to predict relapse in Graves' disease: a questionnaire among patients and internal medicine specialists[J]. J Endocrinol Invest, 2024, 47(10):2499-2505. |
| [34] | FUNG M H M, LUK Y, YUEN K K W, et al. The two-year results of using radiofrequency ablation as a novel treatment for persistent or relapsed Graves' disease: a prospective study[J]. Thyroid, 2024, 34(8):1017-1026. |
| [35] | CAI G, LUO B, WANG M, et al. Efficacy and safety of ultrasound-guided thermal ablation of Graves' disease: a retrospective cohort study[J]. Thyroid Res, 2024, 17(1):10. |
| [36] | MA W, ZHANG X, ZHAO R, et al. Effectiveness and potential mechanism of Jiawei-Xiaoyao-San for hyperthyroidism: a systematic review[J]. Front Endocrinol (Lau-sanne), 2023, 14:1241962. |
| [37] | 张亮, 薛俊, 王燕萍, 等. 疏肝益气汤联合赛治治疗甲状腺功能亢进及对甲状腺上动脉血流动力学的改善作用研究[J]. 中华中医药学刊, 2019, 37(12):3042-3045. |
| ZHANG L, XUE J, WANG Y P, et al. Therapeutic effect of Shugan Yiqi decoction combined with Saizhi on hyperthyroidism and improvement of hemodynamics of superior thyroid artery[J]. Chin Arch Tradit Chin Med, 2019, 37(12):3042-3045. | |
| [38] | FAN L, WANG Z, SUN W, et al. Early identification of postoperative remission for thyrotropin-secreting adenomas[J]. Clin Endocrinol (Oxf), 2024, 101(3):249-254. |
/
| 〈 |
|
〉 |
